Ceftriaxone-associated biliary sludge and pseudolithiasis in children


Onlen Y., Gali E., Incecik F., Deviren M. U., Savas L.

Infectious Diseases in Clinical Practice, vol.15, no.3, pp.167-170, 2007 (Scopus) identifier

Abstract

Detection of incidence and the risk factors of ceftriaxone (CTX)-associated pseudolithiasis (PL) in children. One hundred fourteen patients (75 boys and 39 girls) who used CTX for the treatment of various infections were admitted to the study. Pseudolithiasis was diagnosed by ultrasonography (USG). Ultrasonography was performed at the beginning, on the 5th and 10th days, and at the end of the treatment. Weekly USG was performed to patients who had PL until the findings improved. It was investigated whether the age, sex, weight, treatment duration, dosage, and the way of administration have effects on PL development. Ceftriaxone was administered intravenously. Fifty-seven patients received once-daily and 57 patients received twice-daily dosage. Pseudolithiasis was observed in 37 (32.5%) of 114 patients. Age, sex, weight, treatment duration, and dosage had no role in PL development, whereas once- or twice-daily administration was found effective. Once-daily dosage of CTX treatment is recommended because of its lower incidence of PL development. Besides that USG should be performed regarding the risk of PL in children who are treated with CTX, further studies are necessary to determine the risk factors. © 2007 Lippincott Williams & Wilkins, Inc.